SP100

Across TCGA pan-cancer cohorts, SP100 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SP100 data layer compared with 29 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SP100 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SP100 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

BLCA, STAD, and UCEC are the cancer types where SP100 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.141	0.687	.003	27	view →
STAD	DFS	Median	III,IV	1.000	0.309	.027	22	view →
UCEC	DFS	Median	All	0.923	0.613	.010	14	view →
PRAD	DFS	Median	All	0.118	0.886	<.001	6	view →
LIHC	DFS	Median	II,III,IV	0.038	0.427	<.001	6	view →
LUAD	DFS	Median	All	0.533	0.816	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SP100–BLCA (OS)

Open the BLCA breakdown →